DOJ examining role of over 12 generic drug makers; Charges to be filed by year end: Report

ByGary Kaltbaum November 3, 2016November 3, 2016

Post navigation

Pages

About Gary Kaltbaum
About The Show
Money Management
Consulting
GaryK’s Consulting Service
Educational Lesson GaryK Guide To Insider Buying
Educational Lesson: Understanding Big Stock Market Gaps
Gary K. Newsletter
Contact

Categories

Latest Posts
Radio
Television
Newsletter

Gary Kaltbaum owns Kaltbaum Capital Management, LLC (“KCM”), a state registered investment adviser. The opinions expressed herein are those of Mr. Kaltbaum and may not reflect those of KCM. The information offered in this publication is general information that does not take into account the individual circumstances, financial situation or individual needs of an investor. The information herein has been obtained from sources believed to be reliable, but we cannot assure its accuracy or completeness. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Any reference to past performance is not to be implied or construed as a guarantee of future results.

Charts & Data Courtesy MarketSurge. Click Here To Join MarketSurge.

ABOUT
MONEY MANAGEMENT
COMMENTARY
CONTACT
LISTEN NOW